Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-038045
Filing Date
2025-04-23
Accepted
2025-04-23 16:32:18
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm252437d3_defa14a.htm DEFA14A 10807
2 GRAPHIC tm252437d3_defa14aimg001.jpg GRAPHIC 155817
3 GRAPHIC tm252437d3_defa14aimg002.jpg GRAPHIC 137986
  Complete submission text file 0001104659-25-038045.txt   417128
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33958 | Film No.: 25862041
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)